Stocks · News reference

8-K filing — Cocrystal Pharma, Inc. (COCP)

Sep 9, 2026, 12:00 PMSEC EDGAR

Filed: 2026-09-09 AccNo: 0001493152-26-041877 Size: 223 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: edgar
Observed: Sep 9, 2026, 12:00 PM
Checked: Sep 9, 2026, 12:00 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 9, 2026, 11:10 AMBenzinga Newsdesk
Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Challenge Study Of CDI-988; Says No Serious Adverse Events To Date, Preliminary Efficacy Results Expected Late 2026 Or Early 2027
COCP
BenzingaAug 13, 2026, 12:23 PMBenzinga Newsdesk
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of $(0.20) per share from
COCP
BenzingaAug 3, 2026, 2:22 PMBenzinga Newsdesk
Cocrystal Pharma shares are trading higher after the company announced a $5 million private placement with OPKO Health.
COCP